title: The Belgian MIRA (MabThera In Rheumatoid Arthritis) registry: clues for the optimization of rituximab treatment strategies.
abstract: BACKGROUND
  This study describes the results of the Belgian 'MabThera In Rheumatoid Arthritis (MIRA)' registry: effectiveness, safety and evaluation of the current retreatment practice on the background of the Belgian reimbursement criteria for rituximab.
  
  
  METHODS
  All Belgian rheumatologists had the possibility to participate in the study. Patients entered the registry in November 2006 and the entry is still open.
  
  
  RESULTS
  By mid-September 2009, 401 patients had entered the registry with a mean follow-up time of 70 weeks. Overall, DAS28-ESR decreased from 6.0 at baseline to 4.2 at week 16. Further decrease of disease activity was observed at the end of year 1 and year 2 with mean DAS28-ESR of 4.0 and 3.7 at these respective time points. More than 80% of patients showed a EULAR response at week 16. Patients could be retreated if they had DAS scores of > 3.2 at least 6 months after the previous course. Second and third courses were given in 224 and 104 patients, respectively. At month 6 after the second course, significantly lower DAS28-ESR values were observed compared to the first course. This was especially the case for patients who were retreated before they showed an obvious flare (DAS increase > 1.2).
  
  
  CONCLUSIONS
  This study describes the follow-up of a daily clinical practice cohort of 401 RA patients with long-standing refractory disease treated with rituximab. Relatively high DAS28 values at the start of each retreatment, compared to values 6 months after each treatment course, were noted. Moreover, further decrease of DAS28 scores after the second course was significantly more pronounced in those patients who didn't show an obvious flare. These two elements suggest that treatment of RA patients with rituximab could be optimized by earlier retreatment.
authors.affiliation: Department of Rheumatology, Ghent University Hospital, De Pintelaan 185, 9000 Ghent, Belgium. Bert.VanderCruyssen@Ugent.be.
authors.forename: Bert
authors.initials: B
authors.lastname: Vander Cruyssen
authors.forename: Patrick
authors.initials: P
authors.lastname: Durez
authors.forename: Rene
authors.initials: R
authors.lastname: Westhovens
authors.forename: Marie-Joelle
authors.initials: MJ
authors.lastname: Kaiser
authors.forename: Ilse
authors.initials: I
authors.lastname: Hoffman
authors.forename: Filip
authors.initials: F
authors.lastname: De Keyser
mesh_terms: D058846:Antibodies, Monoclonal, Murine-Derived / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D001530:Belgium; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D012042:Registries; D000069283:Rituximab; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D000069283:Rituximab